摘要:
The present invention provides N-methylethylcarbamino-3-[(S)-1-(methyl-[(S)-1-phenylethyl] amino) ethyl] phenyl ester represented by formula (II) and its preparation method. The present invention also provides (S)-1-(3-methoxyphenyl)-N-methyl-N-[(S)-1-phenylethyl] ethylamine and 3-[(S)-1-(methyl-[(S)-1-phenylethyl] amino) ethyl] phenol as intermediates of the compound represented by formula (II), and the use of the compound represented by formula (II) for preparing rivastigmine used for treating Alzheimer disease.
摘要:
The present invention discloses a process for obtaining 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate (formula I) by the reaction of 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole (formula II), or its hydrolysis product, or its ring-opening product, with alcohol under appropriate catalytic conditions. Furthermore, the present invention also provides a process for obtaining high purity 4,4-dimethyl-2-propyl-4,6-dihydrofuro[3,4-d]imidazole (formula II), therefore purified compound of formula I can be produced. Producing of olmesartan medoxomil at high purity is assured by said processes. R in formula I is selected from C 1 -C 6 alkyl.
摘要:
The present invention discloses a salt derivative of 1-(3-methanesulfonamidobenzyl)-6-methoxy-7-benzyloxy-1,2,3,4-tetrahydroisoquinoline shown in formula I. The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL:
The salt derivative has a solubility in water of not less than 3.0 nmol/mL or 1.8 mg/mL